Unique ID issued by UMIN | C000000039 |
---|---|
Receipt number | R000000079 |
Scientific Title | A phase I/II study of uterine artery embolization using gelatine sponge for symptomatic uterine leiomyoma (JIVROSG-0302) |
Date of disclosure of the study information | 2005/08/05 |
Last modified on | 2012/09/21 13:18:41 |
A phase I/II study of uterine artery embolization using gelatine sponge for symptomatic uterine leiomyoma (JIVROSG-0302)
Uterine artery embolization using gelatine sponge for uterine leiomyoma (JIVROSG-0302)
A phase I/II study of uterine artery embolization using gelatine sponge for symptomatic uterine leiomyoma (JIVROSG-0302)
Uterine artery embolization using gelatine sponge for uterine leiomyoma (JIVROSG-0302)
Japan |
Symptomatic uterine leimoyoma
Obstetrics and Gynecology | Radiology |
Others
NO
To evaluate the safety and efficacy of uterine artery embolization using gelatine sponge in patients with symptomatic uterine leiomyoma.
Safety,Efficacy
Confirmatory
Explanatory
Phase I,II
Adverse events
Improvement of symptoms, decrease of the volume of leiomyoma, changes in ovarian function, length of hospital stay.
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Treatment
Maneuver |
Bilateral uterine arteries are embolized with gelatine sponge particles using microcatheter system inserted by Seldinger's technique. The embolization is terminated when the stasis of blood flow in the ascending branch of uterine arteries is observed.
Not applicable |
Not applicable |
Female
1) Symptomatic uterine leiomyomas confirmed by imaging studies with MRI or US.
2) Uncontrolled symptoms with medical therapies.
3) Premenopausal.
4) Adecuate cardiac, hepatic, renal, respiratory, and bone marrow functions.
5) Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.
6) Written informed consent.
1) Pregnant, nursing, or desiring future pregnancy.
2) Active pelvic inflammatory disease.
3) Pelvic malignancy.
4) Previous hormonal therapy within 12 weeks.
5) Contraindication to MRI.
6) Contraindication to iodized contrast material.
7) Uncontrolled cardiac, respiratory, gastrointestinal, or nervous disorders. Uncontrolled diabetes, hypertension, or infection.
8) Adenomyosis confirmed with MRI.
33
1st name | |
Middle name | |
Last name | Miyuki Sone |
Iwate Medical University
Department of Radiology
19-1, Uchimaru, Morioka 020-8505, Japan
019-651-5111
1st name | |
Middle name | |
Last name | Yasuaki Arai |
JIVROSG, Coordinating Office
Division of Diagnostic Radiology, National Cancer Center Hospital
5-1-1,Tsukiji,Chuo-ku,Tokyo,104-0045,Japan
03-3542-2511
http://jivrosg.umin.jp/
jivrosgoffice@ml.res.ncc.go.jp
Japan Interventional Radiology in Oncology Study Group (JIVROSG)
Ministry of Health, Labour and Welfare
Japan
NO
2005 | Year | 08 | Month | 05 | Day |
http://jivrosg.umin.jp/
Published
http://www.ncbi.nlm.nih.gov/pubmed/20884240
-Technical success was achieved in all patients.
-Median follow-up period was 33 months.
-Minor AEs occurred in 10 pts (33%) and major AEs in two (6%). The most common AE was transient amenorrhea.
-Median hospital stay was five days.
-The rates of symptom improvement at 12 months were: menorrhagia, 90%; pelvic pain,77%;bulk-related symptoms, 96%.
-The mean reduction rate in leiomyoma volume on MRI at 12 month was 61%.
: Presented at SIR 2008, Washington D.C.
Completed
2004 | Year | 02 | Month | 15 | Day |
2004 | Year | 03 | Month | 01 | Day |
2007 | Year | 07 | Month | 01 | Day |
2007 | Year | 10 | Month | 01 | Day |
2007 | Year | 10 | Month | 01 | Day |
2007 | Year | 12 | Month | 01 | Day |
2005 | Year | 08 | Month | 05 | Day |
2012 | Year | 09 | Month | 21 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000000079